中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 11
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(11): 2448-2451

Antiviral therapy for pregnant women and children with chronic HBV infection

DOI: 10.3969/j.issn.1001-5256.2022.11.003

  • Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang 110022, China

Research funding:

National Science and Technology Major Project during the 13th Five-Year Plan Period (2017ZX10201201)

More Information
  • Corresponding author: DING Yang, yding0903@sina.com(ORCID: 0000-0002-7066-2865)
  • Received Date: 2022-07-03
  • Accepted Date: 2022-08-05
  • Published Date: 2022-11-20
    Abstract
  • The most important measure for preventing mother-to-child transmission of HBV and reducing chronic HBV infection in children is enhancing the standardized management of chronic HBV infection in pregnant women and their infants. Pregnant women and children are special populations, and antiviral therapy for pregnant women and children with chronic HBV infection differs from that of general population in terms of drug selection and efficacy evaluation. This article will review the selection and efficacy of antiviral drugs for pregnant women and children with chronic HBV infection, in order to help clinicians manage and treat this special population more effectively.

     

    • FullText(HTML)
  • loading
    • References(40)
  • [1]
    LIU J, WANG XY, WANG Q, et al. Hepatitis B virus infection among 90 million pregnant women in 2853 Chinese counties, 2015-2020: a national observational study[J]. Lancet Reg Health West Pac, 2021, 16: 100267. DOI: 10.1016/j.lanwpc.2021.100267.
    [2]
    DING Y, SHENG QJ, MA L, et al. Chronic HBV infection among pregnant women and their infants in Shenyang, China[J]. Virol J, 2013, 10: 17. DOI: 10.1186/1743-422X-10-17.
    [3]
    World Health Origanization. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral Prophylaxis in Pregnancy[EB/OL]. (2020-07-27)[2021-02-01] https://www.who.int/publications/i/item/978-92-4-000270-8
    [4]
    TERRAULT NA, FELD JJ, LOK ASF. Tenofovir to prevent perinatal transmission of hepatitis B[J]. N Engl J Med, 2018, 378(24): 2348-2349. DOI: 10.1056/NEJMc1805396.
    [5]
    Chinese Society of Infectious Diseases, Chinese Medical Association; China Grade Center. 2019 Chinese practice guideline for prevention and treatment of hepatitis B virus mother-to-child transmission[J]. Chin J Infect Dis, 2019, 37(7): 388-396. DOI: 10.3760/cma.j.issn.1674-2397.2019.05.001.

    中华医学会感染病学分会, 中国Grade中心. 中国乙型肝炎病毒母婴传播防治指南(2019年版)[J]. 中华传染病杂志, 2019, 37(7): 388-396. DOI: 10.3760/cma.j.issn.1674-2397.2019.05.001.
    [6]
    CUI FQ, WOODRING J CHAN P, et al. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China[J]. Int J Epidemiol, 2018, 47(5): 1529-1537. DOI: 10.1093/ije/dyy077.
    [7]
    DING Y, DOU XG. Antiviral treatment strategy of hepatic flare in pregnant women with chronic hepatitis B[J]. Chin J Prac Int Med, 2017, 37(12): 1047-1048. DOI: 10.19538/j.nk2017120103.

    丁洋, 窦晓光. 妊娠期慢性乙型肝炎发作抗病毒治疗策略[J]. 中国实用内科杂志, 2017, 37(12): 1047-1048. DOI: 10.19538/j.nk2017120103.
    [8]
    CUI FQ, SHEN LP, LI L, et al. Prevention of chronic hepatitis B after 3 Decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5): 765-772. DOI: 10.3201/eid2305.161477.
    [9]
    ZHANG HF. Antiviral therapy in children hepatitis B patients[J]. Chin J Hepatol, 2010, 18(7): 495-497. DOI: 10.3760/cma.j.issn.1007-3418.2010.07.006.

    张鸿飞. 儿童慢性乙型肝炎的抗病毒治疗[J]. 中华肝脏病杂志, 2010, 18(7): 495-497. DOI: 10.3760/cma.j.issn.1007-3418.2010.07.006.
    [10]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Management algorithm for prevention mother-to-child transmission of hepatitis B virus (2021)[J]. J Clin Hepatol, 2021, 37(3): 527-531. DOI: 10.3969/j.issn.1001-5256.2021.03.007.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会. 阻断乙型肝炎病毒母婴传播临床管理流程(2021年)[J]. 临床肝胆病杂志, 2021, 37(3): 527-531. DOI: 10.3969/j.issn.1001-5256.2021.03.007.
    [11]
    PAN CQ, DUAN ZP, DAI E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374(24): 2324-2334. DOI: 10.1056/NEJMoa1508660.
    [12]
    CHEN HL, LEE CN, CHANG CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus[J]. Hepatology, 2015, 62(2): 375-386. DOI: 10.1002/hep.27837.
    [13]
    DING Y, CAO LH, ZHU LY, et al. Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study[J]. Aliment Pharmacol Ther, 2020, 52(8): 1377-1386. DOI: doi: 10.1111/apt.16043.
    [14]
    ZENG QL, YU ZJ, JI FP, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study[J]. Clin Infect Dis, 2021, 73(9): e3324-e3332. DOI: 10.1093/cid/ciaa1939.
    [15]
    LI BJ, LIU ZZ, LIU X, et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load[J]. Hepatol Int, 2021, 15(5): 1103-1108. DOI: 10.1007/s12072-021-10235-1.
    [16]
    YANG N, ZHOU GL, CHENG XL, et al. Distribution evaluation of tenofovir in the breast milk of mothers with HBeAg-positive chronic HBV infection after treatment with tenofovir alafenamide and tenofovir disoproxil fumarate by a sensitive UPLC-MS/MS method[J]. Front Pharmacol, 2021, 12: 734760. DOI: 10.3389/fphar.2021.734760.
    [17]
    CHANG CY, AZIZ N, POONGKUNRAN M, et al. Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B[J]. Am J Gastroenterol, 2016, 11(10): 1410-1415. DOI: 10.1038/ajg.2016.296.
    [18]
    KUSHNER T, SHAW PA, KALRA A, et al. Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study[J]. Liver Int, 2018, 38(5): 813-820. DOI: 10.1111/liv.13594.
    [19]
    DING Y, SHENG QJ, ZHANG C, et al. Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection[J]. Chin J Hepatol, 2019, 27(2): 106-111. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.007.

    丁洋, 盛秋菊, 张翀, 等. 慢性乙型肝炎病毒感染孕妇妊娠期肝炎发作的临床特点及抗病毒治疗的疗效[J]. 中华肝脏病杂志, 2019, 27(2): 106-111. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.007.
    [20]
    ZENG QL, ZHANG HX, ZHANG JY, et al. Tenofovir alafenamide for pregnant chinese women with active chronic hepatitis B: a multicenter prospective study[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.12.012.[Online ahead of print]
    [21]
    MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998.e4. DOI: 10.1053/j.gastro.2016.07.012.
    [22]
    XU ZQ, DONG Y, WANG FC, et al. Value of transient elastography in the diagnosis of liver fibrosis in chronic hepatitis B children of different ages[J]. J Clin Hepatol, 2020, 36(6): 78-82. DOI: 10.3969/j.issn.1001-5256.2020.06.016.

    徐志强, 董漪, 王福川, 等. 瞬时弹性成像对不同年龄慢性乙型肝炎肝纤维化患儿的诊断价值[J]. 临床肝胆病杂志, 2020, 36(6): 78-82. DOI: 10.3969/j.issn.1001-5256.2020.06.016.
    [23]
    LIU QC, LIN SW, CAI WP, et al. Analysis of histopathological features of 124 children with chronic hepatitis B[J]. Chin J Exp Clin Viral, 2015, 29(4): 322-325. DOI: 10.3760/cma.j.issn.1003-9279.2015.04.011.

    刘启材, 林思炜, 蔡卫平, 等. 124例儿童慢性乙型肝炎肝组织病理变化特征分析[J]. 中华实验和临床病毒学杂志, 2015, 29(4): 322-325. DOI: 10.3760/cma.j.issn.1003-9279.2015.04.011.
    [24]
    WU JF, TAI CS, CHANG KC, et al. Baseline hepatitis B virus surface antigen titers in childhood predict the risk of advanced liver fibrosis in adulthood[J]. Clin Gastroenterol Hepatol, 2022. DOI: 10.1016/j.cgh.2022.02.046.[Online ahead of print]
    [25]
    DEFRESNE F, ETIENNE SOKAL E. Chronic hepatitis B in children: Therapeutic challenges and perspectives[J]. J Gastroenterol Hepatol, 2017, 32(2): 368-371. DOI: 10.1111/jgh.13459.
    [26]
    XU PF, DENG HL, WANG XY, et al. Short-term efficacy of antiviral therapy for 6 children with chronic hepatitis B[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2020, 14(6): 518-522.

    徐鹏飞, 邓慧玲, 王小燕, 等. 六例慢性乙型肝炎儿童患者抗病毒治疗短期疗效[J/CD]. 中华实验和临床感染病杂志(电子版), 2020, 14(6): 518-522.
    [27]
    HE Y, YIN J, XU H. Efficacy and safety of pegylated interferon for the treatment of chronic hepatitis B in children and adolescents: a systematic review and meta-analysis[J]. Pediatr Infect Dis J, 2020, 39(12): 1121-1126. DOI: 10.1097/INF.0000000000002876.
    [28]
    WIRTH S, ZHANG H, HARDIKAR W, et al. Efficacy and safety of peginterferon alfa-2a (40KD) in children with chronic hepatitis B: the PEG-B-ACTIVE study[J]. Hepatology, 2018, 68(5): 1681-1694. DOI: 10.1002/hep.30050.
    [29]
    NING L, HUANG X, XU Y, et al. Boosting of hepatitis B virus-specific T cell responses after pegylated-Interferon-α-2a therapy for hepatitis B e antigen-positive pediatric patients[J]. J Interferon Cytokine Res, 2019, 39(12): 740-751. DOI: 10.1089/jir.2019.0042.
    [30]
    FAN HM, LIN LP, JIA SJ, et al. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B[J]. J Viral Hepat, 2019, 26(Suppl 1): 77-84. DOI: 10.1111/jvh.13165.
    [31]
    LIU YH, LI H, YAN XH, et al. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B[J]. J Viral Hepat, 2019, 26(Suppl 1): 69-76. DOI: 10.1111/jvh.13154.
    [32]
    JONAS MM, CHANG MH, SOKAL E, et al. Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B[J]. Hepatology, 2016, 63(2): 377-387. DOI: 10.1002/hep.28015.
    [33]
    ZHU SS, DONG Y, WANG LM, et al. Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B[J]. J Hepatol, 2019, 71(5): 871-875. DOI: 10.1016/j.jhep.2019.06.009.
    [34]
    WU JF, CHIU YC, CHANG KC, et al. Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood[J]. Hepatology, 2016, 63(1): 74-82. DOI: 10.1002/hep.28222.
    [35]
    DONG Y, LI MN, ZHU SS, et al. De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis[J]. J Viral Hepat, 2020, 27(12): 1338-1343. DOI: 10.1111/jvh.13372.
    [36]
    KENNEDY PTF, SANDALOVA E, JO J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B[J]. Gastroenterology, 2012, 143(3): 637-645. DOI: 10.1053/j.gastro.2012.06.009.
    [37]
    ZHU SS, ZHANG HF, DONG Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study[J]. J Hepatol, 2018, 68(6): 1123-1128. DOI: 10.1016/j.jhep.2018.01.037.
    [38]
    ROSENTHAL P, LING SC, BELLE SH, et al. Combination of entecavir/peginterferon alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection[J]. Hepatology, 2019, 69(6): 2326-2337. DOI: 10.1002/hep.30312.
    [39]
    PAN J, ZHANG M, YAO TT, et al. Efficiency and influencing factors of interferon therapy for 1-6 years old children with chronic hepatitis B[J]. Int J Virol, 2020, 27(3): 214-218. DOI: 10.3760/cma.j.issn.1673-4092.2020.03.009

    潘静, 张敏, 姚甜甜, 等. 干扰素治疗1~6岁慢性乙型肝炎的疗效及影响因素[J]. 国际病毒学杂志, 2020, 27(3): 214-218. DOI: 10.3760/cma.j.issn.1673-4092.2020.03.009
    [40]
    WANG LM, ZHAO JF, LIU JY et al. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B[J]. J Viral Hepat, 2021, 28(11): 1554-1562. DOI: 10.1111/jvh.13598.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (500) PDF downloads(224) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return